Novo Nordisk signed a collaboration with Vivtex to license oral drug‑delivery technology aimed at converting injectable biologics into pills, with deal economics worth up to $2.1 billion in milestones and tiered royalties. At the same time the company announced a major pricing move—cutting list prices for Wegovy and Ozempic by up to 50% beginning in 2027—citing patient affordability and competitive pressure. The twin actions reposition Novo to compete on both formulation innovation (oral biologics) and price while responding to market and regulatory scrutiny of GLP‑1 costs.